Peptech ASX: PTD - Appoints Global Financial Adviser to Examine Strategic Options - Dr John Chiplin, CEO
Sydney, Mar 14, 2007 (ABN Newswire) - Peptech (ASX: PTD) - Appoints Global Financial Adviser to Examine Strategic Options - Dr John Chiplin, CEO; Boardroomradio is pleased to announce that Peptech (ASX: PTD) has published an audio file. The following presentation "Appoints Global Financial Adviser to Examine Strategic Options" is now available as an instant audio download to your computer. You may also transfer this information to your listening device as an IPod podcast.
The BRR service is based on streaming audio sent in compressed form over the internet and displayed as it arrives. You do not have to wait for the whole file to be downloaded before you can hear it, instead the media is sent in a continuous stream and is played immediately as it reaches your computer. Please note that during live broadcasts there can be a delay of approximately 1-2 minutes, depending on traffic through your Internet Service Provider.
Broadcaster: Peptech (ASX: PTD)
Broadcast Title: Appoints Global Financial Adviser to Examine Strategic Options
Broadcast Type: Audio stream
View the Audio stream for Peptech (ASX: PTD) below.
Peptech Limited focuses on the research and development of peptides and proteins in the areas of human pharmaceuticals and animal health. Peptech holds a 36.1 per cent shareholding in Domantis, a UK-based drug development company, and has formed a 50/50 joint venture company with Biosceptre. The company is positioned to become a globally recognised leader in biopharmaceutical development. For more information, please visit www.peptech.com.
About Arana Therapeutics Limited
Undertake research, development, production, formulation and marketing of peptides, and related products for the the pharmaceutical, veterinary and agricultural industries.
About Boardroomradio
Sydney-based Boardroomradio (BRR) is an Investor Relations multi-media portal delivering audio webcasts to the investment community, including brokers, fund managers, analysts, and private investors.
